Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Jennerex Out-Licenses China Rights for Cancer Drug to Lee’s Pharma

publication date: Nov 19, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Jennerex, Inc., a clinical-stage biotherapeutics company with a novel virus-based treatment for cancer, has licensed the China rights for JX-594 to Lee’s Pharmaceuticals. Jennerex is headquartered in San Francisco, though its R&D operations are in Ottawa, Canada. JX-594 is currently undergoing a Phase II trial to treat hepatocellular carcinoma (HCC), an urgent unmet need in China. More details...

Stock Symbol: (HKEX: 8221)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners